Business Context and Reporting Period
This Form 8-K is a current report filed by MIRA Pharmaceuticals, Inc. on December 17, 2025. The filing details compensation actions approved by the Compensation Committee on December 16, 2025, and ratified by the full Board of Directors on December 17, 2025, for Chief Executive Officer Erez Aminov.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt). However, it discloses specific compensation awards totaling $1,157,258 in cash value plus equity units:
- Short-Term Incentive (STI): $242,258 approved; $80,753 contingent on Phase 1 clinical study completion.
- Transaction Advisory Award: $915,000 for the acquisition of SKNY Pharmaceutical, Inc. (payable in cash, equity, or both).
- Long-Term Incentive (LTI): 62,500 performance share units (PSUs) issued for achieving a market capitalization milestone.
Material Changes
The filing highlights significant operational progress in 2025, including:
- Advancement of clinical development programs.
- Completion of a strategic acquisition of SKNY Pharmaceutical, Inc.
- Execution of capital-raising activities.
- Achievement of the first market capitalization milestone under the CEO's LTI plan.
Guidance, Outlook, and Management Commentary
Management views the SKNY acquisition as strategically important for long-term growth and pipeline expansion. The Board noted continued strengthening of the company's development pipeline and corporate initiatives. No specific financial guidance or forward-looking revenue projections were included in this filing.
Investor Verification Checklist
- Verify the terms and vesting schedule of the 62,500 PSUs granted to the CEO.
- Confirm the status of the Phase 1 clinical study required to release the contingent $80,753 STI payout.
- Review the definitive agreement for the SKNY Pharmaceutical, Inc. acquisition to understand integration risks.
- Check subsequent filings for the specific mix of cash versus equity used for the $915,000 transaction advisory award.